Plus Therapeutics Subsidiary CNSide Diagnostics To Present Data From FORESEE Trial AT SNO Meeting; CNSide Cerebrospinal Fluid Assay Met Key Primary And Secondary Endpoints
Plus Therapeutics Subsidiary CNSide Diagnostics To Present Data From FORESEE Trial AT SNO Meeting; CNSide Cerebrospinal Fluid Assay Met Key Primary And Secondary Endpoints
Plus Therapeutics旗下子公司CNSide诊断将在SNO会议上展示FORESEE试验数据；CNSide脑脊液检测达到主要和次要终点
Key highlights:
柔性与薄型解决方案：
- The FORESEE trial achieved its primary endpoint, demonstrating that CNSide influenced treatment decisions in over 90% of cases evaluated, surpassing the predetermined 20% primary endpoint target
- CNSide demonstrated enhanced sensitivity in detecting tumor cells (80%) vs. CSF cytology (29%) in patients with LM
- CNSide identified actionable mutations in the CSF, such as HER2 amplification, influencing 24% of therapeutic selection decisions
- CNSide exhibited high specificity, with no tumor cells detected in patients without LM
- CNSide demonstrated improved Negative Predictive Value in ruling out LM (25%) vs. CSF cytology (10%)
- CNSide revealed HER2 positivity in LM tumors in 60% of breast cancer patients with HER2-negative primary tumors, informing physician treatment strategies
- FORESEE试验达成了其主要终点，显示CNSide在超过90%的评估案例中影响了治疗决策，超越了预定的20%的主要终点目标
- CNSide在检测肿瘤细胞方面表现出增强的敏感性（80%）与CSF细胞学（29%）相比，在存在LM的患者中
- CNSide在CSF中识别出可操作的突变，如HER2扩增，影响了24%的治疗选择决策
- CNSide表现出高特异性，在没有LM的患者中未检测出肿瘤细胞
- CNSide在排除LM方面的阴性预测值有所改善（25%）与CSF细胞学（10%）相比
- CNSide在60%的HER2阴性原发肿瘤的乳腺癌患者中揭示了LM肿瘤的HER2阳性，指引了医生的治疗策略
热门讨论
科技巨头财报季如火如荼，英伟达压轴会表现如何？
星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星
Moo Earnings
02/02 12:39
亚马逊盈利预告：猜测开盘价，获取奖励！